# A Study to Learn How Well a Combination of Darolutamide and Androgen Deprivation Therapy (ADT) Works as a Treatment Before Surgery for Men Who Have Hi

Source: https://onco.cc/trials/nct07450599/  
OnCo record `nct07450599` (Trial). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)"; commercial use needs a licence.

## TL;DR

A phase 2 trial of Darolutamide in prostate cancer, run by Bayer, now recruiting.

## Summary

A Study to Learn How Well a Combination of Darolutamide and Androgen Deprivation Therapy (ADT) Works as a Treatment Before Surgery for Men Who Have High-risk Localized Prostate Cancer. is a phase 2 interventional study registered as NCT07450599 by Bayer, with 250 participants planned, started 2026-04-27 and due to reach its primary completion in 2028-10-15. Interventions recorded: Darolutamide, ADT. Conditions listed: High-risk Localized Prostate Cancer. No results are recorded here; the registry entry is the source.

## Fields

- Kind: Trial
- Status: recruiting
- Last checked: 2026-09-16
- Tags: ctgov-ingest
- Registry id: NCT07450599
- Phase: 2
- Setting: A China Interventional Phase II, Single Arm, Multicenter Study Evaluating the Effectiveness and Safety of Darolutamide + ADT as Neo-Adjuvant Treatment in Treatment-naïve Patients Who Have Planned for Radical Prostatectomy (RP) With High Risk Localized Prostate Cancer
- Sponsor: Bayer
- Enrolled: 250

## Sources

- ClinicalTrials.gov NCT07450599: https://clinicaltrials.gov/study/NCT07450599

## Connected records

- cancers: [Prostate cancer](https://onco.cc/cancers/prostate/)
- drugs: [Darolutamide](https://onco.cc/drugs/darolutamide/)
- companies: [Bayer](https://onco.cc/companies/bayer/)

---
JSON: https://onco.cc/api/v1/entities/nct07450599.json